161 related articles for article (PubMed ID: 38430249)
1. Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma.
Fan X; Yan Z; Lin Y; Wang Q; Jiang L; Yao X; Dong L; Chen L; Zhao T; Zhao J; Hu H; Wang H
Cancer Immunol Immunother; 2024 Mar; 73(4):62. PubMed ID: 38430249
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
3. Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma.
Yu Z; Li Y; Li Y; Zhang J; Li M; Ji L; Tang Y; Zheng Y; Sheng J; Han Q; Li F; Guo J; Wang L; Sun X; Gao Y; Feng H
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618286
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/β-catenin pathway.
Lv J; Chen FK; Liu C; Liu PJ; Feng ZP; Jia L; Yang ZX; Hou F; Deng ZY
Life Sci; 2020 Sep; 256():117925. PubMed ID: 32522570
[TBL] [Abstract][Full Text] [Related]
5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.
Li Y; Du Y; Sun T; Xue H; Jin Z; Tian J
BMC Cancer; 2018 Jun; 18(1):669. PubMed ID: 29921237
[TBL] [Abstract][Full Text] [Related]
7. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma.
Zhou C; Weng J; Liu C; Liu S; Hu Z; Xie X; Gao D; Zhou Q; Sun J; Xu R; Li H; Shen Y; Yi Y; Shi Y; Sheng X; Dong Q; Hung MC; Ren N
Gastroenterology; 2023 Jun; 164(7):1261-1278. PubMed ID: 36863689
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer.
Zheng Y; Wang PP; Fu Y; Chen YY; Ding ZY
Int Immunopharmacol; 2022 Sep; 110():109030. PubMed ID: 35978519
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
10. Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization.
Xu G; Feng D; Yao Y; Li P; Sun H; Yang H; Li C; Jiang R; Sun B; Chen Y
Oncogene; 2020 Feb; 39(7):1429-1444. PubMed ID: 31659256
[TBL] [Abstract][Full Text] [Related]
11. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
12. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
[TBL] [Abstract][Full Text] [Related]
14. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
[TBL] [Abstract][Full Text] [Related]
15. Quercetin/Anti-PD-1 Antibody Combination Therapy Regulates the Gut Microbiota, Impacts Macrophage Immunity and Reshapes the Hepatocellular Carcinoma Tumor Microenvironment.
Wu R; Xiong J; Zhou T; Zhang Z; Huang Z; Tian S; Wang Y
Front Biosci (Landmark Ed); 2023 Dec; 28(12):327. PubMed ID: 38179731
[TBL] [Abstract][Full Text] [Related]
16. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
17. Effect of Proton Therapy on Tumor Cell Killing and Immune Microenvironment for Hepatocellular Carcinoma.
Chen MF; Chen PT; Hsieh CC; Wang CC
Cells; 2023 Jan; 12(2):. PubMed ID: 36672266
[TBL] [Abstract][Full Text] [Related]
18. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Fan JB; Ke AW; Fan J
J Hepatol; 2022 Jul; 77(1):163-176. PubMed ID: 35219791
[TBL] [Abstract][Full Text] [Related]
19. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8
Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894
[TBL] [Abstract][Full Text] [Related]
20. Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC.
Yang H; Mu W; Yuan S; Yang H; Chang L; Sang X; Gao T; Liang S; Liu X; Fu S; Zhang Z; Liu Y; Zhang N
J Nanobiotechnology; 2024 Mar; 22(1):137. PubMed ID: 38553725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]